HU229103B1 - Self emulsifying drug delivery system - Google Patents
Self emulsifying drug delivery system Download PDFInfo
- Publication number
- HU229103B1 HU229103B1 HU0300539A HUP0300539A HU229103B1 HU 229103 B1 HU229103 B1 HU 229103B1 HU 0300539 A HU0300539 A HU 0300539A HU P0300539 A HUP0300539 A HU P0300539A HU 229103 B1 HU229103 B1 HU 229103B1
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical composition
- oil
- surfactant
- composition according
- compound
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title description 4
- 230000001804 emulsifying effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims description 63
- 239000002775 capsule Substances 0.000 claims description 48
- 239000004094 surface-active agent Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000000839 emulsion Substances 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000007787 solid Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000003921 oil Substances 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 19
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 14
- 229920000159 gelatin Polymers 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000007903 gelatin capsule Substances 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007764 o/w emulsion Substances 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 7
- 229960000502 poloxamer Drugs 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- -1 poly (oxyethylene} Polymers 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000010775 animal oil Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 239000011435 rock Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229920001987 poloxamine Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229920002516 Poloxamer 331 Polymers 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 150000005691 triesters Chemical class 0.000 claims description 2
- 229920002511 Poloxamer 237 Polymers 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 238000011049 filling Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000001828 Gelatine Substances 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 239000012669 liquid formulation Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 229920001992 poloxamer 407 Polymers 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005429 filling process Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SWNIFANHJGMBIM-UHFFFAOYSA-N 2,3-dihydroxypropyl hexadecanoate;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(=O)OCC(O)CO SWNIFANHJGMBIM-UHFFFAOYSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000010742 number 1 fuel oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000774A SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | New formulation |
| PCT/SE2001/000466 WO2001066087A1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0300539A2 HUP0300539A2 (hu) | 2003-07-28 |
| HUP0300539A3 HUP0300539A3 (en) | 2003-09-29 |
| HU229103B1 true HU229103B1 (en) | 2013-07-29 |
Family
ID=20278740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300539A HU229103B1 (en) | 2000-03-08 | 2001-03-06 | Self emulsifying drug delivery system |
Country Status (28)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| SE0102993D0 (sv) * | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
| AU2003900887A0 (en) * | 2003-02-27 | 2003-03-13 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| US8802116B2 (en) | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
| DE10353937A1 (de) * | 2003-11-18 | 2005-06-30 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Übertragung einer Referenzflüssigkeit in ein Messgerät, Messgerät mit einer solchen Vorrichtung und Verfahren zur Übertragung einer Referenzflüssigkeit in ein Messgerät |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| JP2007536268A (ja) * | 2004-05-06 | 2007-12-13 | エミスフェアー・テクノロジーズ・インク | 固体剤形の湿性ヘパリン |
| EP1756039B1 (en) | 2004-05-14 | 2012-10-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| KR100654617B1 (ko) * | 2004-09-23 | 2006-12-08 | 정해현 | 스틱이 내장된 커피믹스 팩과 커피믹스 박스 |
| EP1906938B1 (en) * | 2005-07-26 | 2010-10-20 | NicOx S.A. | Pharmaceutical formulation of nitrooxyderivatives of nsaids |
| CN102036661B (zh) | 2008-03-20 | 2016-12-28 | 维尔恩公司 | 维生素衍生物及其用途 |
| AU2009226019C1 (en) | 2008-03-20 | 2014-02-20 | Virun, Inc. | Emulsions including a PEG-derivative of tocopherol |
| JP5951489B2 (ja) | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組成物 |
| US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
| US9968557B1 (en) | 2011-02-09 | 2018-05-15 | Florida A&M University | Method of preparing modified multilayered microstructures with enhanced oral bioavailability |
| KR20240076240A (ko) * | 2022-11-23 | 2024-05-30 | (주) 바이오인프라생명과학 | 더블 에멀젼 구조의 초음파 감응형 약물전달체를 생성하는 방법 |
| WO2025219169A1 (en) | 2024-04-16 | 2025-10-23 | Bayer Consumer Care Ag | Stable soft capsule preparations with liquid fill for moisture sensitive active ingredients |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| CY1398A (en) | 1981-09-04 | 1987-12-18 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| JPS59227870A (ja) | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規２−グアニジノチアゾリン誘導体ならびにその製造法 |
| US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
| US4522826A (en) | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| US4766117A (en) | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4704278A (en) | 1984-10-17 | 1987-11-03 | American Home Products Corp (Del) | Fluidized magaldrate suspension |
| US4676984A (en) | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
| US4965065A (en) | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
| US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| US5043358A (en) | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
| US5037815A (en) | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5260333A (en) | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| EP0320550A1 (en) | 1987-12-18 | 1989-06-21 | Bristol-Myers Company | Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| NZ235877A (en) | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| JPH06506198A (ja) | 1991-03-04 | 1994-07-14 | ワーナー−ランバート・コンパニー | 種々な剤形の非ステロイド性抗炎症剤の新規な塩／イオン対 |
| DE4131678A1 (de) | 1991-04-13 | 1992-10-15 | Beiersdorf Ag | Stabile multiple emulsionen |
| DK0550083T3 (da) | 1991-12-06 | 1999-10-11 | Glaxo Group Ltd | Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra |
| WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| US5294433A (en) | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| CA2144155A1 (en) | 1992-09-29 | 1994-04-14 | Robert T. Sims | Ibuprofen-h2 antagonist combinations |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| DK66493D0 (da) | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| FR2710535B1 (fr) * | 1993-09-30 | 1995-11-24 | Gattefosse Ets Sa | Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion. |
| US6312704B1 (en) * | 1993-09-30 | 2001-11-06 | Gattefosse, S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| HU218923B (hu) * | 1993-10-06 | 2000-12-28 | Nicox S.A. | Gyulladásgátló és/vagy fájdalomcsillapító hatású nitrát-észterek, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására |
| US5514663A (en) | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
| WO1995011024A1 (en) | 1993-10-19 | 1995-04-27 | The Procter & Gamble Company | Picosulphate dosage form |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US5643960A (en) | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| WO1995030641A1 (en) | 1994-05-10 | 1995-11-16 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| DE69535889D1 (de) | 1994-07-08 | 2009-01-02 | Astrazeneca Ab | Aus vielen Einzeleinheiten zusammengesetzte tablettierte Dosisform |
| SE9500478D0 (sv) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| JPH11504028A (ja) * | 1995-04-24 | 1999-04-06 | イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム | 油／水エマルジョンを作り出す自己乳化性配合物 |
| US5955451A (en) | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| CA2271799A1 (en) | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| US6160020A (en) | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| PT989851E (pt) * | 1997-07-29 | 2002-12-31 | Upjohn Co | Formulacao auto-emulsionante para compostos lipofilicos acidicos |
| US6599529B1 (en) | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
| US6395298B1 (en) | 1997-10-31 | 2002-05-28 | Pharmacia Corporation | Gellan gum tablet coating |
| EP1056457A4 (en) | 1998-01-30 | 2006-10-25 | Sepracor Inc | S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE |
| CA2320963A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| JP2002513750A (ja) * | 1998-05-07 | 2002-05-14 | エラン コーポレーシヨン ピーエルシー | 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム |
| EP0984012A3 (en) | 1998-08-31 | 2001-01-10 | Pfizer Products Inc. | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties |
| ES2234306T3 (es) | 1998-09-28 | 2005-06-16 | Warner-Lambert Company Llc | Administracion enterica y via colon usando capsulas de hpmc. |
| US6485747B1 (en) | 1998-10-30 | 2002-11-26 | Monsanto Company | Coated active tablet(s) |
| JP2002531515A (ja) * | 1998-12-11 | 2002-09-24 | ファーマソリューションズ・インコーポレイテッド | 水に難溶性の薬剤のための自己乳化組成物 |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| JP4638053B2 (ja) | 1999-03-31 | 2011-02-23 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン |
| WO2000071122A1 (en) | 1999-05-20 | 2000-11-30 | Par Pharmaceutical, Inc. | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| US6126816A (en) * | 1999-07-14 | 2000-10-03 | Ruiz, Jr.; Reuben F. | Wastewater treatment device |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| US6787164B2 (en) | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
| SE0000773D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20020045184A1 (en) | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| AR036354A1 (es) | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
| US7467633B2 (en) * | 2005-03-10 | 2008-12-23 | Huntsman Petrochemical Corporation | Enhanced solubilization using extended chain surfactants |
-
2000
- 2000-03-08 SE SE0000774A patent/SE0000774D0/xx unknown
-
2001
- 2001-02-26 AR ARP010100864A patent/AR027554A1/es not_active Application Discontinuation
- 2001-03-06 KR KR1020027011733A patent/KR100771318B1/ko not_active Expired - Fee Related
- 2001-03-06 AU AU2001237875A patent/AU2001237875B2/en not_active Ceased
- 2001-03-06 IL IL15138001A patent/IL151380A0/xx not_active IP Right Cessation
- 2001-03-06 RU RU2002122745/15A patent/RU2275908C2/ru not_active IP Right Cessation
- 2001-03-06 DK DK01910304T patent/DK1267831T3/da active
- 2001-03-06 DE DE60115402T patent/DE60115402T2/de not_active Expired - Lifetime
- 2001-03-06 ES ES01910304T patent/ES2253354T3/es not_active Expired - Lifetime
- 2001-03-06 EP EP01910304A patent/EP1267831B1/en not_active Expired - Lifetime
- 2001-03-06 BR BRPI0109012-7A patent/BR0109012B1/pt not_active IP Right Cessation
- 2001-03-06 CN CNB018062938A patent/CN1283229C/zh not_active Expired - Fee Related
- 2001-03-06 AU AU3787501A patent/AU3787501A/xx active Pending
- 2001-03-06 HU HU0300539A patent/HU229103B1/hu not_active IP Right Cessation
- 2001-03-06 EE EEP200200483A patent/EE200200483A/xx unknown
- 2001-03-06 AT AT01910304T patent/ATE311173T1/de active
- 2001-03-06 CA CA002401857A patent/CA2401857A1/en not_active Abandoned
- 2001-03-06 US US10/221,079 patent/US7736666B2/en not_active Expired - Fee Related
- 2001-03-06 SI SI200130487T patent/SI1267831T1/sl unknown
- 2001-03-06 JP JP2001564740A patent/JP4656479B2/ja not_active Expired - Fee Related
- 2001-03-06 CZ CZ20023006A patent/CZ303524B6/cs not_active IP Right Cessation
- 2001-03-06 MX MXPA02008658A patent/MXPA02008658A/es active IP Right Grant
- 2001-03-06 WO PCT/SE2001/000466 patent/WO2001066087A1/en not_active Ceased
- 2001-03-06 SK SK1258-2002A patent/SK285749B6/sk not_active IP Right Cessation
- 2001-03-07 MY MYPI20011044A patent/MY137749A/en unknown
- 2001-06-03 UA UA2002086882A patent/UA76098C2/uk unknown
-
2002
- 2002-09-03 IS IS6538A patent/IS6538A/is unknown
- 2002-09-03 NO NO20024194A patent/NO331921B1/no not_active IP Right Cessation
- 2002-09-04 ZA ZA200207109A patent/ZA200207109B/en unknown
-
2010
- 2010-04-28 US US12/768,820 patent/US20100266683A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU229103B1 (en) | Self emulsifying drug delivery system | |
| RU2270675C9 (ru) | Новая самоэмульгирующаяся система доставки лекарств | |
| AU2001237875A1 (en) | New self emulsifying drug delivery system | |
| JP4656483B2 (ja) | 新規な自己乳化薬物送達システム | |
| US8252326B2 (en) | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 | |
| TW200517104A (en) | Semi-solid formulations for the oral administration of taxoids | |
| US20240226301A9 (en) | Anhydrous oral pharmaceutical suspensions | |
| MXPA06000100A (en) | Controlled release preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: NICOX S.A., FR Free format text: FORMER OWNER(S): ASTRAZENECA AB,, SE; NICOX S.A., FR |
|
| GB9A | Succession in title |
Owner name: NICOX SCIENCE IRELAND, IR Free format text: FORMER OWNER(S): ASTRAZENECA AB,, SE; NICOX S.A., FR; NICOX S.A., FR |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |